AJR. American journal of roentgenology · 1995
Blood-pool MR contrast material for detection and characterization of focal hepatic lesions: initial clinical experience with ultrasmall superparamagnetic iron oxide (AMI-227).
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Saini S, Edelman R R, Sharma P, Li W, Mayo-Smith W, Slater G J, Eisenberg P J, Hahn P F
Аннотация
OBJECTIVE: AMI-227 is an ultrasmall superparamagnetic iron oxide colloid known to enhance tissue T1 and T2 relaxation rates. Animal studies show that AMI-227 has an estimated blood half-life of more than 200 min. In this study, we evaluated the clinical utility of AMI-227 as an MR contrast agent for detection and characterization of focal hepatic lesions, with MR imaging done while the contrast agent is in the intravascular space (blood-pool phase).
SUBJECTS AND METHODS: Twenty-two patients with known or suspected focal hepatic masses underwent T1- and T2-weighted MR imaging of the liver at 1.5 T before and immediately after drip infusion of AMI-227 at doses of 0.8, 1.1, or 1.7 mg Fe/kg. Unenhanced and contrast-enhanced images were analyzed qualitatively (lesion detection and tissue characterization) and quantitatively (lesion-liver contrast-to-noise ratio).
RESULTS: AMI-227 enhanced signal in normal liver and blood vessels on T1-weighted images and decreased signal in these tissues on T2-weighted images. Qualitatively and quantitatively, lesion-liver contrast was increased for solid tumors (non-cyst and nonhemangioma) at all three doses (p < .02) on both T1- and T2-weighted images. Differentiation between blood vessels and small lesions was easier on contrast-enhanced images, which allowed increased confidence in excluding lesions. Unique enhancement patterns were noted for hemangiomas, solid tumors, and cysts.
CONCLUSION: Initial clinical experience suggests that AMI-227 is a useful contrast agent for detection and characterization of focal hepatic lesions.
SUBJECTS AND METHODS: Twenty-two patients with known or suspected focal hepatic masses underwent T1- and T2-weighted MR imaging of the liver at 1.5 T before and immediately after drip infusion of AMI-227 at doses of 0.8, 1.1, or 1.7 mg Fe/kg. Unenhanced and contrast-enhanced images were analyzed qualitatively (lesion detection and tissue characterization) and quantitatively (lesion-liver contrast-to-noise ratio).
RESULTS: AMI-227 enhanced signal in normal liver and blood vessels on T1-weighted images and decreased signal in these tissues on T2-weighted images. Qualitatively and quantitatively, lesion-liver contrast was increased for solid tumors (non-cyst and nonhemangioma) at all three doses (p < .02) on both T1- and T2-weighted images. Differentiation between blood vessels and small lesions was easier on contrast-enhanced images, which allowed increased confidence in excluding lesions. Unique enhancement patterns were noted for hemangiomas, solid tumors, and cysts.
CONCLUSION: Initial clinical experience suggests that AMI-227 is a useful contrast agent for detection and characterization of focal hepatic lesions.